

17W



Practitioner's Docket No. NEB-214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Xu, Ming-qun; Ghosh, Inca; Sun, Luo; and Evans, Thomas C.

Application No.: 10/733,617
Filed: December 11, 2003
For: Carrier-Ligand Fusions and Uses Thereof
Group No.: Not yet assigned
Examiner: Not yet assigned

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

CERTIFICATION UNDER 37 C.F.R. " 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)
X with sufficient postage as first class mail.

37 C.F.R. § 1.10*
as "Express Mail Post Office to Addressee"
Mailing Label No. _____ (mandatory)

TRANSMISSION

facsimile transmitted to the Patent and Trademark Office, (703) _____




Signature
Leslie Goldberg
(type or print name of person certifying)

Date: September 15, 2004

* Only the date of filing (' 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under ' 1.8 continues to be taken into account in determining timeliness. See ' 1.703(f). Consider "Express Mail Post Office to Addressee" (' 1.10) or facsimile transmission (' 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Date: September 15, 2004



Harriet M. Strimpel, D.Phil.

Registration No. 37,008


New England Biolabs, Inc.

32 Tozer Road

Beverly, MA 01915

978-927-5054, x373

Customer No. 28986



Patitioner's Docket No. NEB-214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Ming-qun Xu, Inca Ghosh, Luo Sun, and Thomas C. Evans

Application No.: 10/733,617

Filed: December 11, 2003

For: Carrier-Ligand Fusions and Uses Thereof

Group No.: Not yet assigned

Examiner: Not yet assigned

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)
2. Copies of Listed Information Items Accompanying This Statement
3. Identification of Person(s) Making This Information Disclosure Statement

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using *Express Mail*, the *Express Mail* label number is *mandatory*;
Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

X with sufficient postage as first class mail.


37 C.F.R. § 1.10*

as "Express Mail Post Office to Addressee"

Mailing Label No. _____ (mandatory)

TRANSMISSION

facsimile transmitted to the Patent and Trademark Office, (703) _____


Signature

Date: September 15, 2004

Leslie Goldberg

(type or print name of person certifying)

* Only the date of filing ('1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under '1.8 continues to be taken into account in determining timeliness. See '1.703(f). Consider "Express Mail Post Office to Addressee" ('1.10) or facsimile transmission ('1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Section 1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

(Insert form(s) PTO/SB/08A [Form 6-2] and/or form(s) PTO/SB/08B [Form 6-2.1].)

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.


AA-AE, BA-BE and CA-DH.

Section 3. Identification of Person Making This Information Disclosure Statement

The person making this certification is:

- a. the practitioner who signs below on the basis of the information supplied by the inventor(s).

Date: September 15, 2004



Harriet M. Strimpel, D. Phil.

Registration No. 37,008

New England Biolabs, Inc.

32 Tozer Road

Beverly, MA 01915

978-927-5054, x373

Customer No. 28986



SECTION 2. FORMS PTO/SB/08A and 08B (formerly Form PTO-1449)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Xu et al. Atty. Docket: NEB-214-US
 Serial No: 10/733,617 Art Group Unit: Not yet assigned
 Date Filed: 12/11/2003 Examiner Name: Not yet assigned
 Invention: Carrier-Ligand Fusions and Uses Thereof

**LIST OF PATENTS AND PUBLICATIONS FOR
 APPLICANT'S INFORMATION DISCLOSURE STATEMENT**

U.S. PATENT DOCUMENTS					
Examiner Initials	Reference Number	Document Number	Issue / Pub Date	Inventor	Class/Subclass
	AA	5,643,758	07/01/1997	Guan et al.	C12P
	AB	5,496,714	03/05/1996	Comb et al.	C12P
	AC	5,834,247	11/10/1998	Comb et al.	C12N
	AD	2002/0151006 A1	10/17/2002	Muir et al.	C12N
	AE	2002/0049152 A1	04/25/2002	Nock et al.	A61K

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Reference Number	Country Code	Document Number	Publication Date	Patentee or Applicant	Class/Subclass
	BA	WO	03/087301	2003-10-23	NEB	C12N
	BB	WO	01/57183	2001-08-09	NEB	C12N
	BC	WO	00/18881	2000-04-06	NEB	C07K
	BD	WO	00/71701	2000-05-23	NEB	C12N
	BE	WO	00/47751	2000-08-17	NEB	C12N

OTHER DOCUMENTS (cont)			
Examiner Initials	Reference Number	Author	Title of Article, Title of Journal, Volume Number, Page Numbers, Date
	CA	Abell et al.	J. Natl. Prod. 48(20):193-202 (1985).
	CB	Briand et al.	J. Immunol. Methods 78(1) 59-69 (1985).
	CC	Chong et al.	Gene 192:271-281 (1997).
	CD	Chong et al.	Nuc. Acids Res. 26:5109-5115 (1998).
	CE	Domen et al.	J. Chromatogr. 510:293-302 (1990).
	CF	Dourtoglou	Synthesis 1984, 572-574 (1984).
	CG	Eisenbarth et al.	Anal. Biochem. 111(1):1-16 (1981).
	CH	Evans et al.	Biopolymers 51(5):333-342 (2000).
	CI	Evans et al.	J. Biol. Chem. 274:3923-3926 (1999).
	CJ	Evans et al.	J. Biol. Chem. 274:18359-18363 (1999).
	CK	Evans et al.	Protein Sci. 7(11):2256-2264 (1998).
	CL	Evans et al.	J. Biol. Chem. 275:9091-9094 (2000).
	CM	Ferrandon et al.	Biochim. Biophys. Acta. 1621:31-40 (2003).
	CN	Fields et al.	Peptide Research 4:95-101 (1991).
	CO	Gonyea et al.	Clin. Chem. 23(2 Pt. 1):234-236 (1977).
	CP	Harlow et al.	Antibodies, Cold Spring Harbor Press: Cold Spring Harbor Laboratory, 1988.
	CQ	Hermanson	Immobilized Affinity Ligand Techniques, Academic Press: San Diego, 1992, pp. 75, 99, 118, 143.
	CR	Hinman et al.	Mol. Immunol. 2(6):681-688 (1985).
	CS	Huse et al.	J. Biochem. Biophys. Methods 51:217-213 (2002).
	CT	Jiskoot et al.	Mol. Immunology 124(1): 143-156 (1985).
	CU	Knorr	Tetrahedron Letters 30:1927-1930 (1989).
	CV	Limberger et al.	Mol. Biochem. Parasitol. 38:271-280 (1990).
	CW	Mathys et al.	Gene 231(12):1-13 (1999).
	CX	Muir et al.	Proc. Natl. Acad. Sci. USA 95:6705-6710 (1998).
	CY	Murray et al.	J. Chromatogr. 40:343-349 (2002).
	CZ	Northwood et al.	J. Biol. Chem. 266:15266-15276 (1991).
	DA	Reimer et al.	Curr. Opin. Biotechnol. 13:315-320 (2002).
	DB	Reineke et al.	Curr. Opin. Biotechnol. 12:59-64 (2001).
	DC	Songyang et al.	Nature 373:536-539 (1995).
	DD	Sun et al.	Journal of Immunol. Methods 282:45-52 (2003).
	DE	Sydor et al.	Bioconjugate Chem. 13:707-712 (2002).
	DF	Templin et al.	Trends Biotechnol. 20:160-166 (2002).
	DG	Welfle et al.	J. Mol. Recognit. 14:89-98 (2001).
	DH	Yelton et al.	Annu. Rev. Biochem. 50:657-680 (1981).

Examiner Signature: _____

Date Considered: _____

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *if not* in conformance and not considered. Include copy of this form with next communication to applicant.